Medicamen Biotech Intrinsic Value
Medicamen Biotech (MEDICAMEQ) median intrinsic value is ₹202.70 from 9 valuation models (range ₹84–₹394), vs current price ₹241.85 — -16.2% downside (Trading Above Median Value), margin of safety -19.3%. Read MEDICAMEQ ex-dividend dates for the complete payout history and dividend yield track record.
MEDICAMEQ Valuation Methods Summary — DCF, Graham Number & P/E
Medicamen Biotech intrinsic value across 9 models vs current price ₹241.85 — upside/downside and value range per method. For current market price and key ratios, visit MEDICAMEQ stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹288.64 | ₹230.91 - ₹346.37 | +19.3% | EPS: ₹13.12, Sector P/E: 22x |
| Book Value Method | asset | ₹394.29 | ₹354.86 - ₹433.72 | +63.0% | Book Value/Share: ₹197.14, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹354.29 | ₹318.86 - ₹389.72 | +46.5% | Revenue/Share: ₹177.14, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹200.00 | ₹180.00 - ₹220.00 | -17.3% | EBITDA: ₹28.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹96.74 | ₹77.39 - ₹116.09 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹83.97 | ₹75.57 - ₹92.37 | -65.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹202.70 | ₹182.43 - ₹222.97 | -16.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹120.92 | ₹108.83 - ₹133.01 | -50.0% | ROE: 5.8%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹241.24 | ₹217.12 - ₹265.36 | -0.3% | EPS: ₹13.12, BVPS: ₹197.14 |
MEDICAMEQ Intrinsic Value vs Market Price — All Valuation Models
Medicamen Biotech fair value range ₹84–₹394 vs current market price ₹241.85 across 9 valuation models. Analyse MEDICAMEQ shareholding pattern to track promoter, FII and institutional holdings.
MEDICAMEQ Intrinsic Value Analysis — Undervalued or Overvalued?
Medicamen Biotech median intrinsic value ₹202.70, current price ₹241.85 — Trading Above Median Value by 16.2%, margin of safety -19.3%.
What is the intrinsic value of MEDICAMEQ?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Medicamen Biotech (MEDICAMEQ) is ₹202.70 (median value). With the current market price of ₹241.85, this represents a -16.2% variance from our estimated fair value.
The valuation range spans from ₹83.97 to ₹394.29, indicating ₹83.97 - ₹394.29.
Is MEDICAMEQ undervalued or overvalued?
Based on our multi-method analysis, Medicamen Biotech (MEDICAMEQ) appears to be trading above median value by approximately 16.2%.
MEDICAMEQ Financial Health — Key Ratios vs Industry Benchmarks
Medicamen Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 24.89 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.67x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MEDICAMEQ Cash Flow Quality — Operating & Free Cash Flow
Medicamen Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-8 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-7 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-6 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹4 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹13 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |